Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H25NO3 |
Molecular Weight | 291.3853 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(O)CCCC2
InChI
InChIKey=SKYSRIRYMSLOIN-UHFFFAOYSA-N
InChI=1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3
Molecular Formula | C17H25NO3 |
Molecular Weight | 291.3853 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ad85b220-6003-4a78-b900-5195ceaf0fd5&typeCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68003519
Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ad85b220-6003-4a78-b900-5195ceaf0fd5&type
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68003519
Cyclopentolate (cyclopentolate hydrochloride) is a parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia. This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). It acts rapidly, but has a shorter duration than atropine. Maximal cycloplegia occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from mydriasis in some individuals may require several days. Heavily pigmented irides may require more doses than lightly pigmented irides.
CNS Activity
Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ad85b220-6003-4a78-b900-5195ceaf0fd5&type
Curator's Comment: This preparation may cause CNS disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger cyclopentolate hydrochloride solutions.
Originator
Sources: http://www.google.ru/patents/US2554511
Curator's Comment: Treves, G.R.; US. Patent 2,554,511; May 29,1951; assigned to Schieffelin & Co.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094109 Sources: https://www.drugbank.ca/drugs/DB00979 |
10.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | PENTOLAIR Approved UseCyclopentolate Hydrochloride Ophthalmic Solution is used to produce mydriasis and cycloplegia in diagnostic procedures. Launch Date1994 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8512760 |
2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered: |
CYCLOPENTOLATE HYDROCHLORIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
324 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8512760 |
2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered: |
CYCLOPENTOLATE HYDROCHLORIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
112 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8512760 |
2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered: |
CYCLOPENTOLATE HYDROCHLORIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1 % 1 times / 5 min multiple, topical Overdose Dose: 1 %, 1 times / 5 min Route: topical Route: multiple Dose: 1 %, 1 times / 5 min Sources: |
unknown, 90 days |
Other AEs: Vomiting, Cyanosis... |
2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Sources: |
Other AEs: Ataxia, Disorder speech... Other AEs: Ataxia Sources: Disorder speech Restlessness Hallucinations Hyperactivity Seizures Confusion and disorientation Other specified visual disturbances |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cyanosis | 1 % 1 times / 5 min multiple, topical Overdose Dose: 1 %, 1 times / 5 min Route: topical Route: multiple Dose: 1 %, 1 times / 5 min Sources: |
unknown, 90 days |
|
Respiratory distress | 1 % 1 times / 5 min multiple, topical Overdose Dose: 1 %, 1 times / 5 min Route: topical Route: multiple Dose: 1 %, 1 times / 5 min Sources: |
unknown, 90 days |
|
Vomiting | 1 % 1 times / 5 min multiple, topical Overdose Dose: 1 %, 1 times / 5 min Route: topical Route: multiple Dose: 1 %, 1 times / 5 min Sources: |
unknown, 90 days |
|
Ataxia | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Sources: |
|
Confusion and disorientation | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Sources: |
|
Disorder speech | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Sources: |
|
Hallucinations | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Sources: |
|
Hyperactivity | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Sources: |
|
Other specified visual disturbances | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Sources: |
|
Restlessness | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Sources: |
|
Seizures | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Retinoscopy in infants using a near noncycloplegic technique, cycloplegia with tropicamide 1%, and cycloplegia with cyclopentolate 1%. | 2001 Apr |
|
Randomised controlled trial of ketorolac in the management of corneal abrasions. | 2001 Apr |
|
Does instilling proxymetacaine before cyclopentolate significantly reduce stinging? The implications of paediatric cycloplegia. | 2001 Feb |
|
[Biochemical stress monitoring during cataract surgery; phenylephrine 10% shows no changes in serum-catecholamines in comparison with phenylephrine 5%]. | 2001 Jul |
|
Efficiency of a video-autorefractometer used as a screening device for amblyogenic factors. | 2002 Sep |
|
Prednisolone and flurbiprofen drops to maintain mydriasis during phacoemulsification cataract surgery. | 2003 Dec |
|
Intracameral mydriatics in phacoemulsification cataract surgery. | 2003 Dec |
|
Acute psychotic reaction caused by topical cyclopentolate use for cycloplegic refraction before refractive surgery: case report and review of the literature. | 2003 May |
|
Parameters of drug antagonism: re-examination of two modes of functional competitive drug antagonism on intraocular muscles. | 2004 Aug |
|
Indocyanine green angiography in ocular tuberculosis. | 2004 Dec |
|
Comparison of the handheld Retinomax K-Plus2 and on-table autokeratometers in children with and without cycloplegia. | 2004 Mar |
|
Grand mal seizure in a child 30 minutes after Cyclogyl (cyclopentolate hydrochloride) and 10% Neo-Synephrine (phenylephrine hydrochloride) eye drops were instilled. | 2004 May |
|
Comparative study on the safety and efficacy of different cycloplegic agents in children with darkly pigmented irides. | 2004 Oct |
|
Drug-induced intraocular lens movement and near visual acuity after AcrySof intraocular lens implantation. | 2005 Jul |
|
Macular star associated with Behçet disease. | 2006 Apr |
|
Redilatation with intracameral mydriatics in phacoemulsification surgery. | 2006 Feb |
Patents
Sample Use Guides
Instill one or two drops of 1% solution in the eye which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from mydriasis in some individuals may require several days.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1848211
Cultured human corneal epithelial cells showed high-affinity, specific binding to the muscarinic cholinergic antagonist, 3H-quinuclidinyl benzilate (3H-QNB). The binding sites had a dissociation constant of 3.9 nM and a maximal binding capacity of 880 fmol bound/mg protein. Other muscarinic antagonists (cyclopentolate and atropine) effectively competed for binding with 3H-QNB at low concentrations (IC50 = 10 nM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:34:43 GMT 2025
by
admin
on
Mon Mar 31 18:34:43 GMT 2025
|
Record UNII |
I76F4SHP7J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
||
|
WHO-VATC |
QS01FA04
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
||
|
WHO-ATC |
S01BB01
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
||
|
WHO-ATC |
S01FA04
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
||
|
WHO-ATC |
S01FA54
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
||
|
NCI_THESAURUS |
C29706
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1201338
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
DB00979
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
SUB06858MIG
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
208-136-4
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
512-15-2
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
I76F4SHP7J
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
4024
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
D003519
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
C61693
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
Cyclopentolate
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
m4011
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | Merck Index | ||
|
2905
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
266
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
I76F4SHP7J
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
Cyclopentolate
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
7153
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
757
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
DTXSID3048528
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
100000083774
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | |||
|
3001
Created by
admin on Mon Mar 31 18:34:43 GMT 2025 , Edited by admin on Mon Mar 31 18:34:43 GMT 2025
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |